ANTILYMPHOCYTIC ANTIBODIES AND MARROW TRANSPLANTATION

Publisher Website
Google Scholar
Abstract
An approach to block secondary disease was investigated in mice sensitized against the Th-1.1 (.theta.-AKR) alloantigen on the marrow donor''s T [thymus-derived] cells. To avoid a concomitant sensitization against the donor''s histocompatibility antigens, prospective marrow recipients were sensitized against thymocytes of a 3rd-party strain sharing the donor''s Th-1 alloantigen but not his histocompatibility antigens. Advantage was taken of the fact that rats carry a Th-1,1-like .theta.-antigen which induces anti-Th-1.1 antibodies in Th-1.2 mice. CBA/J and (C57BL/6 .times. CBA)F1 Th-1.2 mice were sensitized against rat thymocytes and transfused with spleen and bone marrow of AKR/J Th-1.1 after irradiation with 800 to 900 R. Although unsensitized recipients died within 3 wk of acute secondary disease, sensitized mice survived the observation period of 50 days as chimeras. Sensitized recipients were killed by the transplantation of spleen cells from congenic AKR/Cum carrying the Th-1.2 antigen. The host-vs.-.theta.-graft approach suppressed secondary disease following H-2-compatible and -incompatible marrow grafts. Its hemopoietic and T cell chimeras tolerated skin grafts of the donor strain while rejecting 3rd-party skin grafts.

This publication has 1 reference indexed in Scilit: